ReviewJournal of obesity2019
Cardiac Obesity and Cardiac Cachexia: Is There a Pathophysiological Link?
Review in Journal of obesity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Heart failure and its progression is associated with changed lymphocyte profile in epicardial adipose tissue.Frontiers in immunology · 2026Article
- Association of metabolic score for visceral fat with cardiovascular risk and total mortality in patients with type 2 diabetes: insights from ACCORD study.Diabetology & metabolic syndrome · 2025Article
- Guidelines for diet-induced models of cardiometabolic syndrome.American journal of physiology. Heart and circulatory physiology · 2025Review
- Partial obesity paradox regarding mortality in patients hospitalized with diastolic or systolic heart failure.Future cardiology · 2025Article
- The Role of Obesity as a Cardiac Disease Risk Factor in Patients with Type 2 Diabetes.Current cardiology reports · 2024Review
- In Patients Presenting with an ST-Elevation Myocardial Infarction, Overweight and Obese Patients Have the Lowest Inpatient Mortality whereas Cachexia Patients Have the Highest Inpatient Mortality Followed by Patients with Morbid Obesity.Journal of clinical medicine · 2024Article
- Potential role of resveratrol in prevention and therapy of diabetic complications: a critical review.Food & nutrition research · 2024Review
- Depression Predicts Cardiac Cachexia in Heart Failure Patients.Biological research for nursing · 2023Article
- Adiponectin Can Be an Early Predictable Marker for Type 2 Diabetes Mellitus and Nephropathy.Cureus · 2022Article
- Interconnection between Cardiac Cachexia and Heart Failure-Protective Role of Cardiac Obesity.Cells · 2022Review
- Right Heart Morphology and Its Association With Excessive and Deficient Cardiac Visceral Adipose Tissue.Clinical Medicine Insights. Cardiology · 2021Review
- Ryanodine Receptor Type 2: A Molecular Target for Dichlorodiphenyltrichloroethane- and Dichlorodiphenyldichloroethylene-Mediated Cardiotoxicity.Toxicological sciences : an official journal of the Society of Toxicology · 2020Article
- Pericardial fat volume and coronary atherosclerotic markers among body mass index groups.Clinical cardiology · 2020Article
- From Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA) to Chronic Coronary Syndrome: Clinical Diagnostic Use of Laser Doppler Flowmetry in Coronary Microvascular Dysfunction.The American journal of case reports · 2020Article
- Obesity Paradox Occurs in Non-ST-elevation Myocardial Infarction for Overweight and Obesity but Not for Morbid Obesity.Heart views : the official journal of the Gulf Heart AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a risk factor for cardiometabolic and vascular diseases like arterial hypertension, diabetes mellitus type 2, dyslipidaemia, and atherosclerosis. A special role in obesity-related syndromes is played by cardiac visceral obesity, which includes epicardial adipose tissue and intramyocardial fat, leading to cardiac steatosis; hypertensive heart disease; atherosclerosis of epicardial coronary artery disease; and ischemic cardiomyopathy, cardiac microcirculatory dysfunction, diabetic cardiomyopathy, and atrial fibrillation. Cardiac expression of these changes in any given patient is unique and multimodal, varying in clinical settings and level of expressed changes, with heart failure development depending on pathophysiological mechanisms with preserved, midrange, or reduced ejection fraction. Progressive heart failure with misbalanced metabolic and catabolic processes will change muscle, bone, and fat mass and function, with possible changes in the cardiac fat state from excessive accumulation to reduction and cardiac cachexia with a worse prognosis. The question we address is whether cardiac obesity or cardiac cachexia is to be more feared.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.